Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025987 | 0.84 | PTPRC (0.36) | PTPRCPTPN6PTPN11PTPN22CYP2A6 | |
| SCHEMBL30565319 | 0.83 | PTPRC (0.53) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL1104448 | 0.83 | PTPRC (0.53) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL12778757 | 0.80 | ESR1 (0.44) | ALDH1A1PTPRCPTPN6PTPN11PTPN22 | |
| SCHEMBL161509 | 0.79 | PTPRC (0.45) | PTPRCPTPN6PTPN11PTPN22MEN1 | |
| SCHEMBL26315531 | 0.78 | PTPRC (0.32) | PTPRCPTPN6PTPN11PTPN22 | |
| SCHEMBL15582380 | 0.78 | PTPRC (0.42) | PTPRCPTPN6PTPN11PTPN22 | |
| SCHEMBL6089544 | 0.76 | LCK (0.45) | PTPRCPTPN6PTPN11PTPN22CCR9 | |
| SCHEMBL25572184 | 0.76 | PTPRC (0.31) | PTPRCPTPN6PTPN11PTPN22SLC6A2 | |
| SCHEMBL25572299 | 0.75 | PTPRC (0.33) | PTPRCPTPN6PTPN11PTPN22CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | Petragen, Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20090321688-A1 | Carbon Nanotube Composition, Composite Having a Coated Film Composed of the Same, and Their Production Methods | MITSUBISHI RAYON CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080221197-A1 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-20080221197-A1 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | ALDH1A1 1034/4885HPGD 1402/4885ALOX15 3383/4885 |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | ALDH1A1 4266/4885HPGD 1615/4885ALOX15 3726/4885 |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | PI4KB, BTK, LTK | ALDH1A1 4370/4885HPGD 4547/4885ALOX15 4520/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | ALDH1A1 3152/4885HPGD 2680/4885ALOX15 4198/4885 |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | ALDH1A1 4269/4885HPGD 713/4885ALOX15 3393/4885 |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | ALDH1A1 894/4885HPGD 507/4885ALOX15 1271/4885 |
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | ALDH1A1 4610/4885HPGD 2370/4885ALOX15 1552/4885 |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | ALDH1A1 837/4885HPGD 973/4885ALOX15 3278/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | ALDH1A1 648/4885HPGD 1777/4885ALOX15 2143/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | ALDH1A1 2583/4885HPGD 3374/4885ALOX15 818/4885 |
| US-20080221197-A1 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | ALDH1A1 2665/4885HPGD 1340/4885ALOX15 693/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | ALDH1A1 3127/4885HPGD 615/4885ALOX15 3969/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | ALDH1A1 1034/4885HPGD 1402/4885ALOX15 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.